Brain, Vol. 125, No. 8, 1908-1922,
August 2002
© 2002 Guarantors of Brain
Impaired glutamate transport and glutamate–glutamine cycling: downstream effects of the Huntington mutation
1 Department of Neurology, Universitätsklinik Freiburg, 2 Department of Neurology, Universitätsklinik Ulm, Germany and 3 Division of Medical and Molecular Genetics, Guy’s Hospital, London, UK
Correspondence to: Peter F. Behrens, MD, Department of Neurology, Universitätsklinik, Breisacherstrasse 64, 79106 Freiburg, Germany E-mail: pfbehrens{at}web.de
The pathogenesis of Huntington’s disease is still not completely understood. Several lines of evidence from toxic/non-transgenic animal models of Huntington’s disease suggest that excitotoxic mechanisms may contribute to the pathological phenotype. Evidence from transgenic animal models of Huntington’s disease, however, is sparse. To explore potential alterations in brain glutamate handling we studied transgenic mice expressing an N-terminal fragment of mutant huntingtin (R6/2). Intracerebral microdialysis in freely moving mice showed similar extracellular glutamate levels in R6/2 and littermate controls. However, partial inhibition of glutamate transport by L-trans-pyrrolidine-2,4-dicarboxylate (4 mM) disclosed an age-dependent increase in extracellular glutamate levels in R6/2 mice compared with controls, consistent with a reduction of functional glutamate transport capacity. Biochemical studies demonstrated an age-dependent downregulation of the glial glutamate transporter GLT-1 mRNA and protein, resulting in a progressive reduction of transporter function. Glutamate transporters other than GLT-1 were unchanged. In addition, increased extracellular glutamine levels and alterations to glutamine synthetase immunoreactivity suggested a perturbation of the glutamate–glutamine cycle. These findings demonstrate that the Huntington’s disease mutation results in a progressively deranged glutamate handling in the brain, beginning before the onset of symptoms in mice. They also provide evidence for a contribution of excitotoxicity to the pathophysiology of Huntington’s disease, and thus Huntington’s disease may be added to the growing list of neurodegenerative disorders associated with compromised glutamate transport capacity.
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  P. Pacher, S. Batkai, and G. Kunos The Endocannabinoid System as an Emerging Target of Pharmacotherapy Pharmacol. Rev., September 1, 2006; 58(3): 389 - 462. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. R. Pears, J. D. Cooper, H. M. Mitchison, R. J. Mortishire-Smith, D. A. Pearce, and J. L. Griffin High Resolution 1H NMR-based Metabolomics Indicates a Neurotransmitter Cycling Deficit in Cerebral Tissue from a Mouse Model of Batten Disease J. Biol. Chem., December 30, 2005; 280(52): 42508 - 42514. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J.-Y. Shin, Z.-H. Fang, Z.-X. Yu, C.-E. Wang, S.-H. Li, and X.-J. Li Expression of mutant huntingtin in glial cells contributes to neuronal excitotoxicity J. Cell Biol., December 19, 2005; 171(6): 1001 - 1012. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 H. D. Rosas, N. D. Hevelone, A. K. Zaleta, D. N. Greve, D. H. Salat, and B. Fischl Regional cortical thinning in preclinical Huntington disease and its relationship to cognition Neurology, September 13, 2005; 65(5): 745 - 747. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J.-C. Lievens, T. Rival, M. Iche, H. Chneiweiss, and S. Birman Expanded polyglutamine peptides disrupt EGF receptor signaling and glutamate transporter expression in Drosophila Hum. Mol. Genet., March 1, 2005; 14(5): 713 - 724. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. Petersen, J. Gil, M. L.C. Maat-Schieman, M. Bjorkqvist, H. Tanila, I. M. Araujo, R. Smith, N. Popovic, N. Wierup, P. Norlen, et al. Orexin loss in Huntington's disease Hum. Mol. Genet., January 1, 2005; 14(1): 39 - 47. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 P. R. LOUZADA, A. C. P. LIMA, D. L. MENDONCA-SILVA, F. NOEL, F. G. DE MELLO, and S. T. FERREIRA Taurine prevents the neurotoxicity of {beta}-amyloid and glutamate receptor agonists: activation of GABA receptors and possible implications for Alzheimer's disease and other neurological disorders FASEB J, March 1, 2004; 18(3): 511 - 518. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
H. Guo, L. Lai, M. E.R. Butchbach, M. P. Stockinger, X. Shan, G. A. Bishop, and C.-l. G. Lin Increased expression of the glial glutamate transporter EAAT2 modulates excitotoxicity and delays the onset but not the outcome of ALS in mice Hum. Mol. Genet., October 1, 2003; 12(19): 2519 - 2532. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
H. Li, T. Wyman, Z.-X. Yu, S.-H. Li, and X.-J. Li Abnormal association of mutant huntingtin with synaptic vesicles inhibits glutamate release Hum. Mol. Genet., August 15, 2003; 12(16): 2021 - 2030. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. Cepeda, R. S. Hurst, C. R. Calvert, E. Hernandez-Echeagaray, O. K. Nguyen, E. Jocoy, L. J. Christian, M. A. Ariano, and M. S. Levine Transient and Progressive Electrophysiological Alterations in the Corticostriatal Pathway in a Mouse Model of Huntington's Disease J. Neurosci., February 1, 2003; 23(3): 961 - 969. [Abstract] [Full Text] [PDF]
|
|